GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Net Cash per Share

IsoPlexis (IsoPlexis) Net Cash per Share : $-0.76 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). IsoPlexis's Net Cash per Share for the quarter that ended in Dec. 2022 was $-0.76.

The historical rank and industry rank for IsoPlexis's Net Cash per Share or its related term are showing as below:

During the past 4 years, the highest Price-to-Net-Cash Ratio of IsoPlexis was 4.42. The lowest was 0.00. And the median was 4.42.

ISO's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.955
* Ranked among companies with meaningful Price-to-Net-Cash only.

IsoPlexis Net Cash per Share Historical Data

The historical data trend for IsoPlexis's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Net Cash per Share Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Cash per Share
0.63 35.08 2.08 -0.76

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 0.93 0.23 -0.21 -0.76

Competitive Comparison of IsoPlexis's Net Cash per Share

For the Medical Devices subindustry, IsoPlexis's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IsoPlexis's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Price-to-Net-Cash falls into.



IsoPlexis Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

IsoPlexis's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(37.465-67.801-0)/39.6712
=-0.76

IsoPlexis's Net Cash per Share for the quarter that ended in Dec. 2022 is calculated as

Net Cash per Share (Q: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(37.465-67.801-0)/39.6712
=-0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IsoPlexis  (NAS:ISO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


IsoPlexis Net Cash per Share Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IsoPlexis (IsoPlexis) Business Description

Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003